The Prognosis Value of PSPC1 Expression in Nasopharyngeal Cancer

References

• Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet. 2016;387(10022):1012–1024. doi:10.1016/S0140-6736(15)00055-026321262
   PubMed Web of Science ®Google Scholar
• Tang LL, Chen WQ, Xue WQ, et al. Global trends in incidence and mortality of nasopharyngeal carcinoma. Cancer Lett. 2016;374(1):22–30. doi:10.1016/j.canlet.2016.01.04026828135
   PubMed Web of Science ®Google Scholar
• Wei KR, Zheng RS, Zhang SW, Liang ZH, Li ZM, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer. 2017;36(1):90. doi:10.1186/s40880-017-0257-929122009
   PubMedGoogle Scholar
• Caponigro F, Longo F, Ionna F, Perri F. Treatment approaches to nasopharyngeal carcinoma: a review. Anticancer Drugs. 2010;21(5):471–477. doi:10.1097/CAD.0b013e328337160e20124988
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen QY, Liu H, Tang LQ, Mai HQ. Emerging treatment options for nasopharyngeal carcinoma. Drug Des Devel Ther. 2013;7:37–52. doi:10.2147/DDDT.S30753
   PubMed Web of Science ®Google Scholar
• Lee AW, Ma BB, Ng WT, Chan AT. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33(29):3356–3364. doi:10.1200/JCO.2015.60.934726351355
   PubMed Web of Science ®Google Scholar
• Lin S, Pan J, Han L, et al. Update report of nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy and hypothesis of the optimal margin. Radiother Oncol. 2014;110(3):385–389. doi:10.1016/j.radonc.2014.01.01124560755
   PubMed Web of Science ®Google Scholar
• Zhang MX, Li J, Shen GP, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51(17):2587–2595. doi:10.1016/j.ejca.2015.08.00626318726
   PubMed Web of Science ®Google Scholar
• Kam MK, Wong FC, Kwong DL, Sze HC, Lee AW. Current controversies in radiotherapy for nasopharyngeal carcinoma (NPC). Oral Oncol. 2014;50(10):907–912. doi:10.1016/j.oraloncology.2013.09.01324126221
   PubMed Web of Science ®Google Scholar
• Perri F, Della Vittoria Scarpati G, Caponigro F, et al. Management of recurrent nasopharyngeal carcinoma: current perspectives. Onco Targets Ther. 2019;12:1583–1591. doi:10.2147/OTT.S18814830881013
   PubMed Web of Science ®Google Scholar
• Liu SC, Tsang NM, Chiang WC, et al. Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. J Clin Invest. 2013;123(12):5269–5283. doi:10.1172/JCI6342824270418
   PubMed Web of Science ®Google Scholar
• Qu C, Zhao Y, Feng G, et al. RPA3 is a potential marker of prognosis and radioresistance for nasopharyngeal carcinoma. J Cell Mol Med. 2017;21(11):2872–2883. doi:10.1111/jcmm.1320028557284
   PubMed Web of Science ®Google Scholar
• Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-031178151
   PubMed Web of Science ®Google Scholar
• Chen W, Hu GH. Biomarkers for enhancing the radiosensitivity of nasopharyngeal carcinoma. Cancer Biol Med. 2015;12(1):23–32. doi:10.7497/j.issn.2095-3941.2014.001525859408
   PubMed Web of Science ®Google Scholar
• Fox AH, Lam YW, Leung AK, et al. Paraspeckles: a novel nuclear domain. Curr Biol. 2002;12(1):13–25. doi:10.1016/s0960-9822(01)00632-711790299
   PubMed Web of Science ®Google Scholar
• Yeh HW, Hsu EC, Lee SS, et al. PSPC1 mediates TGF-β1 autocrine signalling and Smad2/3 target switching to promote EMT, stemness and metastasis. Nat Cell Biol. 2018;20(4):479–491. doi:10.1038/s41556-018-0062-y29593326
   PubMed Web of Science ®Google Scholar
• Sasaki YT, Ideue T, Sano M, Mituyama T, Hirose T. MENepsilon/beta noncoding RNAs are essential for structural integrity of nuclear paraspeckles. Proc Natl Acad Sci U S A. 2009;106(8):2525–2530. doi:10.1073/pnas.080789910619188602
   PubMed Web of Science ®Google Scholar
• Gao X, Kong L, Lu X, et al. Paraspeckle protein 1 (PSPC1) is involved in the cisplatin induced DNA damage response–role in G1/S checkpoint. PLoS One. 2014;9(5):e97174. doi:10.1371/journal.pone.009717424819514
   PubMed Web of Science ®Google Scholar
• Chen LL, Carmichael GG. Altered nuclear retention of mRNAs containing inverted repeats in human embryonic stem cells: functional role of a nuclear noncoding RNA. Mol Cell. 2009;35(4):467–478. doi:10.1016/j.molcel.2009.06.02719716791
   PubMed Web of Science ®Google Scholar
• Wang J, Rajbhandari P, Damianov A, et al. RNA-binding protein PSPC1 promotes the differentiation-dependent nuclear export of adipocyte RNAs. J Clin Invest. 2017;127(3):987–1004. doi:10.1172/JCI8948428192372
   PubMed Web of Science ®Google Scholar
• Gao X, Zhang G, Shan S, et al. Depletion of Paraspeckle Protein 1 enhances methyl methanesulfonate-induced apoptosis through mitotic catastrophe. PLoS One. 2016;11(1):e0146952. doi:10.1371/journal.pone.014695226785254
   PubMed Web of Science ®Google Scholar
• Wang Z, Fan P, Zhao Y, et al. NEAT1 modulates herpes simplex virus-1 replication by regulating viral gene transcription. Cell Mol Life Sci. 2017;74(6):1117–1131. doi:10.1007/s00018-016-2398-427783096
   PubMed Web of Science ®Google Scholar
• Guallar D, Bi X, Pardavila JA, et al. RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control in pluripotent stem cells. Nat Genet. 2018;50(3):443–451. doi:10.1038/s41588-018-0060-929483655
   PubMed Web of Science ®Google Scholar
• Lang YD, Chen HY, Ho CM, et al. PSPC1-interchanged interactions with PTK6 and β-catenin synergize oncogenic subcellular translocations and tumor progression. Nat Commun. 2019;10(1):5716. doi:10.1038/s41467-019-13665-631844057
   PubMed Web of Science ®Google Scholar
• Kummoona R, Mohammad Sámi S, Al-Kapptan I, Al-Muala H. Study of antiapoptotic gene of oral carcinoma by using Bcl-2 oncogene. J Oral Pathol Med. 2008;37(6):345–351. doi:10.1111/j.1600-0714.2007.00624.x18248353
   PubMed Web of Science ®Google Scholar
• Lin S, Pan J, Han L, Zhang X, Liao X, Lu JJ. Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys. 2009;75(4):1071–1078. doi:10.1016/j.ijrobp.2008.12.01519362784
   PubMed Web of Science ®Google Scholar
• Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16(4):1310–1317. doi:10.1200/JCO.1998.16.4.13109552031
   PubMed Web of Science ®Google Scholar
• Guigay J. Advances in nasopharyngeal carcinoma. Curr Opin Oncol. 2008;20(3):264–269. doi:10.1097/CCO.0b013e3282fad84618391624
   PubMed Web of Science ®Google Scholar
• Yan H, Cao X, Wang J. Application of intensity-modulated radiation therapy in the treatment of nasopharyngeal carcinoma. Oncol Lett. 2017;14(6):7773–7776. doi:10.3892/ol.2017.718629344223
   PubMed Web of Science ®Google Scholar
• Chen X, Lei H, Liang Z, Li L, Qu S, Zhu X. Intensity-modulated radiotherapy controls nasopharyngeal carcinoma distant metastasis and improves survival of patients. Springerplus. 2016;5(1):1459. doi:10.1186/s40064-016-3117-127652034
   PubMedGoogle Scholar
• Guo Y, Zhu XD, Qu S, et al. Identification of genes involved in radioresistance of nasopharyngeal carcinoma by integrating gene ontology and protein-protein interaction networks. Int J Oncol. 2012;40(1):85–92. doi:10.3892/ijo.2011.117221874234
   PubMed Web of Science ®Google Scholar
• Lang YD, Jou YS. PSPC1: a contextual determinant of tumor progression. Mol Cell Oncol. 2020;7(2):1721253. doi:10.1080/23723556.2020.172125332158931
   PubMed Web of Science ®Google Scholar
• Zhang Z, He T, Huang L, et al. Two precision medicine predictive tools for six malignant solid tumors: from gene-based research to clinical application. J Transl Med. 2019;17(1):405. doi:10.1186/s12967-019-02151-831796117
   PubMed Web of Science ®Google Scholar
• Kessler SM, Hosseini K, Hussein UK, et al. Hepatocellular carcinoma and nuclear paraspeckles: induction in chemoresistance and prediction for poor survival. Cell Physiol Biochem. 2019;52(4):787–801. doi:10.33594/00000005530946555
   PubMedGoogle Scholar
• Silva JM, Boczek NJ, Berres MW, Ma X, Smith DI. LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation. RNA Biol. 2011;8(3):496–505. doi:10.4161/rna.8.3.1480021532345
   PubMed Web of Science ®Google Scholar
• Sun X, Su S, Chen C, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol. 2014;110(3):398–403. doi:10.1016/j.radonc.2013.10.02024231245
   PubMed Web of Science ®Google Scholar
• Mao YP, Tang LL, Chen L, et al. Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy. Chin J Cancer. 2016;35(1):103. doi:10.1186/s40880-016-0167-228031050
   PubMedGoogle Scholar
• Yeh HW, Lee SS, Chang CY, Lang YD, Jou YS, New A. Switch for TGFβ in cancer. Cancer Res. 2019;79(15):3797–3805. doi:10.1158/0008-5472.CAN-18-201931300476
   PubMed Web of Science ®Google Scholar
• Hu J, Huang Q, Gao J, et al. Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma. Cancer. 2020;126(23):5173–5183. doi:10.1002/cncr.3319732931035
   PubMed Web of Science ®Google Scholar
• Li S, Li Z, Shu FJ, Xiong H, Phillips AC, Dynan WS. Double-strand break repair deficiency in NONO knockout murine embryonic fibroblasts and compensation by spontaneous upregulation of the PSPC1 paralog. Nucleic Acids Res. 2014;42(15):9771–9780. doi:10.1093/nar/gku65025100870
   PubMed Web of Science ®Google Scholar